COVID-19 与 CAR T 细胞：EHA-IDWP 的 EPICOVIDEHA 调查对当前挑战和未来方向的报告。
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.
机构信息
Stem Cell Transplant Center, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy.
Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
出版信息
Blood Adv. 2022 Apr 12;6(7):2427-2433. doi: 10.1182/bloodadvances.2021005616.
Abstract
The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
摘要
EHA-IDWP 开发了一个观察性登记处，收集接受 CAR T 细胞治疗的患者 COVID-19 感染的数据。COVID-19 的患病率为 4.8%，总死亡率为 50%，这突出表明需要预防这些患者感染。
相似文献
1
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.
Blood Adv. 2022 Apr 12;6(7):2427-2433. doi: 10.1182/bloodadvances.2021005616.
2
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.
Leukemia. 2024 Sep;38(9):1985-1991. doi: 10.1038/s41375-024-02336-1. Epub 2024 Jul 23.
3
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
J Vis Exp. 2019 Dec 17(154). doi: 10.3791/59949.
4
Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Front Immunol. 2022 Jul 14;13:871661. doi: 10.3389/fimmu.2022.871661. eCollection 2022.
5
Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas.
Hematol Oncol Clin North Am. 2023 Dec;37(6):1107-1124. doi: 10.1016/j.hoc.2023.05.017. Epub 2023 Jun 23.
6
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Front Immunol. 2018 Jul 31;9:1717. doi: 10.3389/fimmu.2018.01717. eCollection 2018.
7
CAR-T cells for cancer immunotherapy-the barriers ahead and the paths through.
Int Rev Immunol. 2022;41(6):567-581. doi: 10.1080/08830185.2022.2080820. Epub 2022 May 28.
8
Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
J Control Release. 2024 Apr;368:372-396. doi: 10.1016/j.jconrel.2024.02.033. Epub 2024 Mar 6.
9
Engineering enhanced CAR T-cells for improved cancer therapy.
Nat Cancer. 2021 Aug;2(8):780-793. doi: 10.1038/s43018-021-00241-5. Epub 2021 Aug 19.
10
Advances and Challenges of CAR T Cells in Clinical Trials.
Recent Results Cancer Res. 2020;214:93-128. doi: 10.1007/978-3-030-23765-3_3.
引用本文的文献
1
Meta-analysis of mortality factors after COVID-19 infection in pediatric oncology patients.
Front Oncol. 2025 Aug 6;15:1594617. doi: 10.3389/fonc.2025.1594617. eCollection 2025.
2
Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies.
Antibodies (Basel). 2025 Jun 24;14(3):52. doi: 10.3390/antib14030052.
3
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy.
Ann Hematol. 2025 Jun 4. doi: 10.1007/s00277-025-06425-8.
4
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study.
JMIR Res Protoc. 2025 May 26;14:e60675. doi: 10.2196/60675.
5
Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective.
Infect Dis Ther. 2025 Apr;14(4):671-733. doi: 10.1007/s40121-025-01124-3. Epub 2025 Mar 18.
6
Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.
JAMA Netw Open. 2025 Feb 3;8(2):e2461683. doi: 10.1001/jamanetworkopen.2024.61683.
7
Chimeric antigen receptor T-cell therapy in autoimmune diseases.
Front Immunol. 2024 Nov 19;15:1492552. doi: 10.3389/fimmu.2024.1492552. eCollection 2024.
8
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19.
Semin Hematol. 2024 Oct;61(5):321-332. doi: 10.1053/j.seminhematol.2024.08.002. Epub 2024 Aug 23.
9
Chimeric antigen receptor-T-cell therapies going viral: latent and incidental viral infections.
Curr Opin Infect Dis. 2024 Dec 1;37(6):526-535. doi: 10.1097/QCO.0000000000001066. Epub 2024 Oct 3.
10
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.
Leukemia. 2024 Sep;38(9):1985-1991. doi: 10.1038/s41375-024-02336-1. Epub 2024 Jul 23.
本文引用的文献
1
EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19.
Hemasphere. 2021 Jun 25;5(7):e612. doi: 10.1097/HS9.0000000000000612. eCollection 2021 Jul.
2
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.
Leukemia. 2021 Oct;35(10):2885-2894. doi: 10.1038/s41375-021-01302-5. Epub 2021 Jun 2.
3
CAR-T cell therapy: current limitations and potential strategies.
Blood Cancer J. 2021 Apr 6;11(4):69. doi: 10.1038/s41408-021-00459-7.
4
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.
Lancet Haematol. 2021 Mar;8(3):e185-e193. doi: 10.1016/S2352-3026(20)30429-4. Epub 2021 Jan 19.
5
Immunologic characterization of COVID-19 patients with hematological cancer.
Haematologica. 2020 Dec 17;106(5):1457-1460. doi: 10.3324/haematol.2020.269878.
6
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.
Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.
7
COVID-19 in hematopoietic cell transplant recipients.
Bone Marrow Transplant. 2021 Apr;56(4):952-955. doi: 10.1038/s41409-020-01084-x. Epub 2020 Oct 28.
8
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation.
J Clin Invest. 2020 Dec 1;130(12):6656-6667. doi: 10.1172/JCI141777.
9
Risk factors and outcome of COVID-19 in patients with hematological malignancies.
Exp Hematol Oncol. 2020 Aug 25;9:21. doi: 10.1186/s40164-020-00177-z. eCollection 2020.
10
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.
Zotero 插件